Carbamylated erythropoietin ameliorates hypoxia-induced cognitive and behavioral defects with the generation of choline acetyltransferase-positive neurons

Journal of Neuroscience Research

Volumn 91, Issue 1, 2013, Pages 73-82

  Ding, Jing ^a,b   Li, Qin Ying ^a   Yu, Jie Zhong ^c   Wang, Xin ^b   Lu, Chuan Zhen ^a   Ma, Cun Gen ^c   Xiao, Bao Guo ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANXI DATONG UNIVERSITY   (China)

Author keywords

Carbamylated erythropoietin; ChAT; Cognitive defect; Hypoxia

Indexed keywords

BROXURIDINE; CARBAMYLATED ERYTHROPOIETIN; CHOLINE ACETYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CARBAMOYLATION; CELL PROLIFERATION; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SYNTHESIS; ERYTHROPOIESIS; HYPOXIA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANOXIA; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; ERYTHROPOIETIN; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 84869178002     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23124     Document Type: Article

References (43)

1. Adamson JW, Eschbach J, Finch CA. 1968. The kidney and erythropoiesis. Am J Med 44: 725-733.
2. Adembri C, Massagrande A, Tani A, Miranda M, Margheri M, De Gaudio R, Pellegrini-Giampietro DE. 2008. Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit Care Med 36: 975-978.
3. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P. 2002. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952: 128-134.
4. Andoh T, Echigo N, Kamiya Y, Hayashi M, Kudoh I, Goto T. 2011. Effects of erythropoietin on intracellular calcium concentration of rat primary cortical neurons. Brain Res 1387: 8-18.
5. Byts N, Sirén AL. 2009. Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med 21: 1-4.
6. Cariou A, Claessens YE, Pène F, Marx JS, Spaulding C, Hababou C, Casadevall N, Mira JP, Carli P, Hermine O. 2008. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation 76: 397-404.
7. Chen G, Zhang S, Shi J, Ai J, Hang C. 2009. Effects of recombinant humanerythropoietin (rhEPO) on JAK2/STAT3 pathway and endothelial apoptosis in the rabbit basilar artery after subarachnoid hemorrhage. Cytokine 45: 162-168.
8. Constantinescu SN, Ghaffari S, Lodish HF. 1999. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 10: 18-23.
9. Digicaylioglu M, Lipton SA. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-647.
10. Ding J, Li QY, Yu JZ, Wang X, Sun CH, Lu CZ, Xiao BG. 2010. Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. Mol Cell Neurosci 43: 201-208.
11. Elia D, Madhala D, Ardon E, Reshef R, Halevy O. 2007. Sonic hedgehog promotes proliferation and differentiation of adult muscle cells: involvement of MAPK/ERK and PI3K/Akt pathways. Biochim Biophys Acta 1773: 1438-1446.
12. Fantacci M, Bianciardi P, Caretti A, Coleman TR, Cerami A, Brines M, Samaja M. 2006. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci U S A 103: 17531-17536.
13. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. 2005. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102: 2046-2051.
14. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. 2003. PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998.
15. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, Calapai G, De Vico G, Piedimonte G, Salpietro FM, Tomasello F. 2002. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 99: 5627-5631.
16. Ioka T, Tsuruoka S, Ito C, Iwaguro H, Asahara T, Fujimura A, Kusano E. 2009. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients. Clin Pharmacol Ther 86: 154-159.
17. Kadota T, Shingo T, Yasuhara T, Tajiri N, Kondo A, Morimoto T, Yuan WJ, Wang F, Baba T, Tokunaga K, Miyoshi Y, Date I. 2009. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis. Brain Res 1254: 120-127.
18. Khan AA, Mao XO, Banwait S, Jin K, Greenberg DA. 2007. Neuroglobin attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer phenotype in vivo. Proc Natl Acad Sci U S A 104: 19114-19119.
19. King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT. 2007. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 26: 90-100.
20. Kirkeby A, Torup L, Bochsen L, Kjalke M, Abel K, Theilgaard-Monch K, Johansson PI, Bjørn SE, Gerwien J, Leist M. 2008. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 99: 720-728.
21. Kumral A, Gonenc S, Acikgoz O, Sonmez A, Genc K, Yilmaz O, Gokmen N, Duman N, Ozkan H. 2005. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 87: 15-18.
22. Lapchak PA, Kirkeby A, Zivin JA, Sager TN. 2008. Therapeutic window for carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res 1238: 208-214.
23. Leconte C, Bihel E, Lepelletier FX, Bout V, Saulnier R, Petit E, Boulouard M, Bernaudin M, Schumann-Bard P. 2011. Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology 60: 354-364.
24. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. 2004. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242.
25. Li G, Ma R, Huang C, Tang Q, Fu Q, Liu H, Hu B, Xiang J. 2008. Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neurosci Lett 442: 143-147.
26. Mahmood A, Lu D, Qu C, Goussev A, Zhang ZG, Lu C, Chopp M. 2007. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 107: 392-397.
27. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. 2008. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 48: 1754-1762.
28. Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, Van Bee, J, Leist M, Brines M, Cerami A, Ghezzi P. 2006. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 12: 153-160.
29. Minnerup J, Heidrich J, Rogalewski A, Schabitz WR, Wellmann J. 2009. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 40: 3113-3120.
30. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI. 2006. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316: 999-1005.
31. Morton JP, Mongeau ME, Klimstra DS, Morris JP, Lee YC, Kawaguchi Y, Wright CV, Hebrok M, Lewis BC. 2007. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 104: 5103-5108.
32. Naga A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. 2001. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001: 386-392.
33. Richmond TD, Chohan M, Barber DL. 2005. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15: 146-155.
34. Schmidt RE, Green KG, Feng D, Dorsey DA, Parvin CA, Lee JM, Xiao Q, Brines M. 2008. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 209: 161-170.
35. Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. 2001. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98: 4044-4049
36. Tabira T, Konishi Y, Gallyas FJ. 1995. Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro. Int J Dev Neurosci 13: 241-252.
37. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P. 2003. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198: 971-975.
38. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. 2004. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35: 1732-1737.
39. Wang L, Zhang ZG, Gregg SR, Zhang RL, Jiao Z, LeTourneau Y, Liu X, Feng Y, Gerwien J, Torup L, Leist M, Noguchi CT, Chen ZY, Chopp M. 2007. The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem 282: 32462-32470.
40. Wang Y, Zhang ZG, Rhodes K, Renzi M, Zhang RL, Kapke A, Lu M, Pool C, Heavner G, Chopp M. 2007. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 151: 1377-1384.
41. Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y. 2009. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 146: 506-514.
42. Xue YQ, Zhao LR, Guo WP, Duan WM. 2007. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 146: 1245-1258.
43. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. 2008. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 3: e1924.